3.37
+0.04(+1.20%)
Currency In USD
| Previous Close | 3.33 |
| Open | 3.18 |
| Day High | 3.53 |
| Day Low | 3.17 |
| 52-Week High | 6.94 |
| 52-Week Low | 1.11 |
| Volume | 4.07M |
| Average Volume | 3.69M |
| Market Cap | 596.5M |
| PE | -2.37 |
| EPS | -1.42 |
| Moving Average 50 Days | 4.98 |
| Moving Average 200 Days | 3.1 |
| Change | 0.04 |
If you invested $1000 in Prime Medicine, Inc. (PRME) since IPO date, it would be worth $219.26 as of November 16, 2025 at a share price of $3.37. Whereas If you bought $1000 worth of Prime Medicine, Inc. (PRME) shares 2 years ago, it would be worth $547.97 as of November 16, 2025 at a share price of $3.37.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Prime Medicine to Present at Jefferies Global Healthcare Conference
GlobeNewswire Inc.
Nov 11, 2025 1:00 PM GMT
CAMBRIDGE, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Allan Reine, M.D., Chie
Prime Medicine Appoints Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer
GlobeNewswire Inc.
Nov 03, 2025 1:01 PM GMT
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the appointment of Matthew H
Prime Medicine to Host Virtual KOL Event to Showcase Wilson’s Disease Strategy
GlobeNewswire Inc.
Oct 30, 2025 8:01 PM GMT
-- Webcast event to begin at 8:00am ET on Wednesday, November 12, 2025 --CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time